Biotech Values

[DewDiligence]

VTRS Investor Day slide deck shows 2026 as “anticipated launch date” for Botox-biosimilar collaboration with RVNC:

https://investor.viatris.com/static-files/b01a07f3-e549-4522-8480-c31b359a6a4f (slide #14)

If this pans out it will generate material cash flow for RVNC in the next couple of years. The collaboration has $70M of remaining clinical and regulatory milestone payments. The collaboration also has up to $225M of sales-based milestones, although these presumably won’t be triggered until later in the decade.